AC
CBAY

Armistice Capital’s Cymabay Therapeutics CBAY Stock Holding History

Armistice Capital’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-836,000
Closed -$1.62M – 43
2015
Q3 		$1.62M Buy
+836,000
New +$2.28M 0.55% 34

Other funds holding CBAY

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
LOAMU
Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return

Armistice Capital's CBAY Position: Q4 2015 in Review

Armistice Capital sold out of Cymabay Therapeutics (CBAY) in Q4 2015, closing a stake of 836,000 shares — an estimated $1.62M sold.

Armistice Capital first reported a position in CBAY in Q3 2015 and held it in 1 quarter. The position peaked at $1.62M in Q3 2015. 29 funds tracked by Wall St. Rank hold CBAY as of Q4 2015.

  • Armistice Capital reported no remaining Cymabay Therapeutics position as of Q4 2015 after selling out during the quarter.
  • Armistice Capital sold 836,000 Cymabay Therapeutics shares in Q4 2015, an estimated $1.62M.
  • Armistice Capital first reported a position in Cymabay Therapeutics in Q3 2015 and held it in 1 quarter.
  • Armistice Capital's Cymabay Therapeutics position peaked at $1.62M in Q3 2015.
  • 29 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q4 2015.

Based on Armistice Capital's 13F filing for Q4 2015, filed 16 Feb 2016.